GO:0006552 L-leucine catabolic process: Metabolic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006552 (L-leucine catabolic process) describes the chemical reactions and pathways that break down L-leucine, a branched-chain amino acid, into smaller metabolites.
• The term is a biological_process in the Gene Ontology and is distinct from leucine biosynthesis or transport, although transport steps can influence catabolic flux.
• L-leucine catabolism is relevant to metabolic engineering, where modulating aminotransferases and redox flux improves L-leucine production in Corynebacterium glutamicum.
• In host-microbe interactions, L-leucine and its catabolic intermediates can alter metabolomes and affect pathogens such as Streptococcus iniae.
• L-leucine and its derivatives influence cell death pathways, including L-leucyl-L-leucine methyl ester-induced cytotoxicity that is suppressed by MiT/TFE family members.
• Studying GO:0006552 requires integrating genetic, biochemical, and omics approaches, and CRISPR-based models enable causal testing of candidate catabolic genes.
Description
GO:0006552, L-leucine catabolic process, is the Gene Ontology biological process that covers the chemical reactions and pathways resulting in the breakdown of L-leucine. L-leucine is a branched-chain amino acid whose catabolism intersects with energy metabolism, nitrogen handling, and the production of acetyl-CoA and other intermediates. Because the term is defined by the fate of L-leucine rather than by a single enzyme, it encompasses multiple enzymatic steps and can be studied at the levels of metabolite flux, enzyme activity, and gene expression. Researchers working on metabolic engineering, host-pathogen interactions, and amino acid homeostasis frequently need to annotate genes to this term to describe their role in leucine degradation. The QuickGO definition provides a precise scope: the reactions and pathways that result in L-leucine breakdown, which helps distinguish catabolism from biosynthesis, transport, or signaling functions. This article summarizes the definition, mechanistic stages, key genes, disease links, and experimental methods relevant to GO:0006552, with all factual claims supported by the verified literature listed below.
L-leucine catabolic process At A Glance
| GO ID | GO:0006552 |
|---|---|
| GO term | L-leucine catabolic process |
| Ontology | biological_process |
| Synonym | leucine catabolic process; L-leucine breakdown; L-leucine catabolism; L-leucine degradation; L-leucine degradation via Ehrlich pathway; L-methionine catabolic process via Ehrlich pathway |
| Major function | Breakdown of L-leucine into downstream metabolites through enzymatic reactions |
| Related processes | Branched-chain amino acid catabolism, acetyl-CoA production, nitrogen metabolism |
| Cellular context | Occurs in multiple compartments depending on organism, including cytoplasm and mitochondria |
| Research relevance | Metabolic engineering, host-microbe interactions, amino acid homeostasis, cell death modulation |
What Is GO:0006552?
In plain terms, GO:0006552 describes the biochemical steps that cells use to dismantle L-leucine. The official QuickGO definition states that it is the chemical reactions and pathways resulting in the breakdown of L-leucine. This process is a biological_process and includes enzymatic conversions that convert L-leucine into downstream metabolites. It is not the same as leucine biosynthesis, leucine transport, or leucine sensing; those are separate GO terms. The term is often used when annotating genes whose products catalyze or regulate leucine degradation, such as aminotransferases and dehydrogenases involved in branched-chain amino acid catabolism. Because the definition is metabolite-centric, any pathway that consumes L-leucine and produces breakdown products can be considered part of this process.
Why Is L-leucine catabolic process Important in Cell Biology?
GO:0006552 matters because L-leucine catabolism sits at the intersection of energy production, nitrogen disposal, and metabolic signaling. In biotechnology, controlling leucine breakdown is essential for engineering strains that overproduce L-leucine, as shown by optimizing aminotransferases and redox flux in Corynebacterium glutamicum. In infection biology, L-leucine and its catabolic intermediates can reshape host metabolomes and influence pathogen survival, as demonstrated for Streptococcus iniae. In cell biology, leucine derivatives such as L-leucyl-L-leucine methyl ester trigger cell death that is modulated by MiT/TFE family members, linking catabolic or lysosomal pathways to cytotoxicity. In clinical nutrition, branched-chain amino acids including L-leucine are studied for their impact on malnutrition and sarcopenia in chronic liver disease. Finally, transport of L-leucine across barriers such as the inner blood-retinal barrier affects its availability for catabolism, highlighting the need to separate transport from degradation when interpreting GO annotations.
• Provides a defined annotation target for genes involved in L-leucine breakdown, improving functional genomics and pathway analysis.
• Supports metabolic engineering strategies to increase L-leucine production by redirecting catabolic flux.
• Helps explain how L-leucine and its derivatives influence host-pathogen interactions and microbial metabolomes.
• Connects leucine catabolism to cell death pathways through compounds such as L-leucyl-L-leucine methyl ester.
• Informs studies of branched-chain amino acid metabolism in chronic liver disease, malnutrition, and sarcopenia.
• Requires distinguishing catabolism from transport, as L-type amino acid transporter 1 mediates L-leucine uptake at the inner blood-retinal barrier.
• Enables CRISPR-based causal testing of candidate catabolic genes in engineered cell and microbial models.
• Facilitates cross-species comparison of leucine degradation pathways in bacteria, fungi, and mammals.
What Happens During L-leucine catabolic process?
Initial deamination and transamination
In simple terms: The first step often removes the amino group from L-leucine, converting it into a keto acid.
L-leucine catabolism typically begins with deamination or transamination, where the amino group is transferred or removed to yield alpha-ketoisocaproate. In Corynebacterium glutamicum, optimizing aminotransferases alters the balance between leucine biosynthesis and catabolism, demonstrating that these enzymes are central to flux through the pathway. In engineered Escherichia coli, multistep metabolic engineering has been used to modulate L-leucine levels, indirectly reflecting the importance of catabolic steps in controlling the intracellular pool. These reactions are part of the broader branched-chain amino acid catabolic machinery and are annotated under GO:0006552 when they result in L-leucine breakdown.
Oxidative decarboxylation and acyl-CoA formation
In simple terms: After the amino group is removed, the carbon skeleton is further processed and activated for energy production.
Following transamination, the keto acid derived from L-leucine undergoes oxidative decarboxylation to form an acyl-CoA intermediate. This step links leucine catabolism to acetyl-CoA and other metabolic intermediates. In metabolic engineering studies, altering redox flux in C. glutamicum improved L-leucine production, indicating that the redox balance of these oxidative steps influences pathway output. The same principle applies in E. coli, where multistep engineering of L-leucine production required balancing catabolic and anabolic fluxes. These reactions are part of the chemical transformations that result in L-leucine breakdown under GO:0006552.
Formation of downstream metabolites
In simple terms: The breakdown products of L-leucine enter other metabolic pathways, such as energy production or lipid synthesis.
The catabolism of L-leucine yields metabolites that can feed into the tricarboxylic acid cycle or other biosynthetic routes. In host-microbe studies, L-leucine-induced changes in the metabolome of Streptococcus iniae suggest that leucine catabolic intermediates affect microbial physiology. In mammalian systems, L-leucine and its derivatives can influence cell death, as shown by the suppression of L-leucyl-L-leucine methyl ester-induced cell death by MiT/TFE family members. These downstream effects illustrate why GO:0006552 is not merely a degradative endpoint but a source of bioactive metabolites.
Compartmentalization and transport considerations
In simple terms: Where L-leucine is taken up and where it is broken down can be different, so transport must be considered separately.
L-leucine catabolism occurs in specific cellular compartments depending on the organism, and transport steps can regulate substrate availability. For example, L-type amino acid transporter 1 mediates L-leucine transport at the inner blood-retinal barrier, which affects how much leucine reaches catabolic enzymes in the retina. This distinction is important because GO:0006552 covers breakdown reactions, not transport. Researchers annotating genes to this term should ensure that the gene product directly participates in L-leucine degradation rather than only in its uptake or sensing.
Physiological and clinical context
In simple terms: How fast L-leucine is broken down can affect muscle, liver, and overall nutrition.
The rate of L-leucine catabolism influences systemic branched-chain amino acid levels, which are relevant to malnutrition, sarcopenia, and chronic liver disease. In clinical nutrition studies, L-leucine and other branched-chain amino acids have been evaluated for their impact on patient outcomes, highlighting the importance of understanding catabolic flux. In biotechnology, the same pathway is manipulated to increase L-leucine production, showing that catabolism can be either a target for inhibition or a source of intermediates depending on the goal. Thus, GO:0006552 has both basic and applied significance across organisms.
Key Genes Involved in GO:0006552 L-leucine catabolic process
The following genes and proteins are experimentally or functionally associated with L-leucine catabolic process (GO:0006552) in the verified literature, including aminotransferases, transporters, and regulatory factors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Aminotransferases (e.g., ilvE in C. glutamicum) | Catalyze transamination of L-leucine and related branched-chain amino acids | Optimized to improve L-leucine production in Corynebacterium glutamicum |
| Redox flux genes (e.g., in C. glutamicum) | Modulate NADH/NADPH balance affecting catabolic and anabolic steps | Altered to improve L-leucine production |
| E. coli metabolic engineering targets | Multistep pathway genes controlling L-leucine pool | Engineered for high-level L-leucine production |
| SLC7A5 (LAT1) | Mediates L-leucine transport across cellular barriers | Studied at the inner blood-retinal barrier, affecting substrate availability for catabolism |
| MiT/TFE family members | Regulate lysosomal and metabolic responses affecting leucine derivative-induced cell death | Suppress L-leucyl-L-leucine methyl ester-induced cell death |
| Streptococcus iniae metabolic genes | Respond to L-leucine and influence metabolome | L-leucine-induced metabolome changes eliminate this pathogen |
| Branched-chain amino acid catabolic enzymes | Catalyze breakdown of L-leucine to downstream metabolites | General targets for studying GO:0006552 |
| Acetyl-CoA-producing enzymes | Generate acetyl-CoA from leucine-derived carbon skeletons | Link leucine catabolism to energy metabolism |
| Aminotransferase isozymes | Provide redundancy in leucine transamination | Relevant for genetic knockout studies of catabolism |
| Dehydrogenase complexes | Oxidative decarboxylation of keto acids | Affect redox balance and pathway flux |
| Transporters for branched-chain amino acids | Regulate uptake of L-leucine | Distinguish transport from catabolism in annotations |
| Regulatory kinases (e.g., mTOR-related) | Sense leucine availability and modulate metabolism | Indirectly influence catabolic flux |
| Lysosomal hydrolases | Process leucine-containing peptides | Linked to L-leucyl-L-leucine methyl ester effects |
| Metabolome-associated genes in S. iniae | Mediate response to L-leucine | Targets for anti-infective studies |
| E. coli production strain genes | Balance leucine biosynthesis and catabolism | Used in multistep metabolic engineering |
| C. glutamicum production strain genes | Control aminotransferase and redox flux | Improved L-leucine yield |
How Is L-leucine catabolic process Regulated?
The regulation of L-leucine catabolic process is not fully captured by a single regulator in the verified literature, but several studies point to metabolic and redox control. In Corynebacterium glutamicum, altering redox flux changes L-leucine production, indicating that the catabolic pathway is sensitive to the NADH/NADPH balance. Optimizing aminotransferases also modulates flux through leucine metabolism, suggesting that enzyme abundance and specificity are key regulatory nodes. In Escherichia coli, multistep metabolic engineering demonstrates that catabolic and anabolic fluxes must be coordinately regulated to achieve high L-leucine levels. In mammalian systems, MiT/TFE family members suppress L-leucyl-L-leucine methyl ester-induced cell death, linking lysosomal and metabolic regulation to leucine derivative responses. Additionally, L-leucine transport via SLC7A5/LAT1 can regulate substrate availability for catabolism at barriers such as the inner blood-retinal barrier. Clinically, branched-chain amino acid levels including L-leucine are studied in chronic liver disease, where nutritional status and disease state may influence catabolic flux.
L-leucine catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC7A5 (LAT1) | Retinal transport and leucine availability | Knockout or knockdown in retinal cell models |
| MiT/TFE family members | L-leucyl-L-leucine methyl ester-induced cell death | Overexpression or knockout in cultured cells |
| Streptococcus iniae metabolic genes | Host-pathogen interaction and metabolome changes | Bacterial knockout and infection models |
| Branched-chain amino acid catabolic genes | Malnutrition, sarcopenia, chronic liver disease | Metabolic flux assays in cell or animal models |
| C. glutamicum aminotransferases | Metabolic engineering of L-leucine production | Gene knockout or overexpression in C. glutamicum |
Metabolic and nutritional disorders
L-leucine catabolism is relevant to malnutrition, sarcopenia, and chronic liver disease, where branched-chain amino acid levels are altered. Clinical studies have evaluated the impact of L-leucine and other branched-chain amino acids on patient outcomes, highlighting the need to understand catabolic flux in these conditions. Because GO:0006552 describes the breakdown of L-leucine, genes annotated to this term may influence systemic leucine availability and therefore nutritional status.
Host-pathogen interactions
L-leucine and its catabolic intermediates can affect microbial pathogens. In Streptococcus iniae, L-leucine-induced metabolome changes were associated with elimination of the pathogen, suggesting that leucine metabolism influences host-microbe interactions. This makes GO:0006552 relevant to infection biology and to studies of how leucine availability shapes microbial survival.
Cell death and lysosomal dysfunction
Leucine derivatives such as L-leucyl-L-leucine methyl ester can induce cell death, and MiT/TFE family members suppress this effect. This links leucine-related catabolic or lysosomal pathways to cytotoxicity and cell survival. Researchers studying GO:0006552 may therefore investigate how leucine breakdown products or derivatives contribute to cell death regulation.
Retinal and transport-related biology
L-type amino acid transporter 1 mediates L-leucine transport at the inner blood-retinal barrier, which can affect leucine availability for catabolism in the retina. Although transport is not part of GO:0006552, understanding it is necessary to interpret how leucine reaches catabolic enzymes in specific tissues.
From L-leucine catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene directly catalyze L-leucine breakdown? | CRISPR knockout of the gene followed by metabolite profiling |
| Does a point mutation alter enzyme activity in leucine catabolism? | CRISPR point mutation knock-in in a model cell line |
| Can a catabolic gene be tagged for localization studies? | Knock-in of a fluorescent or affinity tag at the endogenous locus |
| Does overexpression of a catabolic gene change leucine flux? | CRISPR-mediated overexpression or cDNA overexpression |
| Which genes regulate leucine-dependent cell death? | CRISPR knockout library screening with L-leucyl-L-leucine methyl ester treatment |
| How does leucine catabolism affect host-pathogen outcomes? | Bacterial knockout and host cell co-culture models |
How to Study the L-leucine catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Metabolomics | Levels of L-leucine and catabolic intermediates | Assessing pathway flux in engineered strains or infected cells |
| Enzyme activity assay | Catalytic activity of aminotransferases or dehydrogenases | Validating candidate catabolic enzymes |
| CRISPR knockout screening | Genes required for leucine catabolism or leucine-induced phenotypes | Identifying novel regulators of GO:0006552 |
| CRISPR point mutation | Effect of specific amino acid changes on enzyme function | Testing catalytic residues in catabolic enzymes |
| Tagged knock-in | Subcellular localization of catabolic enzymes | Determining compartmentalization of leucine breakdown |
| Overexpression | Gain-of-function effects on leucine flux | Testing whether a gene enhances catabolism |
| Metabolic flux analysis | Rate of L-leucine consumption and product formation | Quantifying pathway activity in production strains |
| Host-pathogen co-culture | Impact of leucine metabolism on microbial survival | Studying infection biology related to GO:0006552 |
Metabolomics and flux analysis
Metabolomics can measure L-leucine and its catabolic intermediates to assess pathway activity. In Streptococcus iniae, L-leucine-induced metabolome changes were characterized to understand how leucine affects the pathogen. In metabolic engineering, metabolite profiling helps quantify the impact of genetic modifications on L-leucine production and catabolism. These approaches are essential for linking genotype to metabolic phenotype under GO:0006552.
Enzyme activity assays
Direct enzyme assays measure the catalytic activity of aminotransferases and dehydrogenases involved in L-leucine breakdown. Optimizing aminotransferases in Corynebacterium glutamicum required assessing their activity and specificity, demonstrating the value of biochemical assays. Such assays can be combined with genetic perturbations to determine which enzymes are rate-limiting for catabolism.
Genetic and CRISPR screens
CRISPR knockout or interference screens can identify genes required for L-leucine catabolism or for responses to leucine derivatives. For example, MiT/TFE family members were shown to suppress L-leucyl-L-leucine methyl ester-induced cell death, a finding that could be extended using CRISPR screens. In bacteria, targeted knockouts of metabolic genes help define their role in leucine metabolism. These approaches provide causal evidence for gene function in GO:0006552.
Transport and localization studies
Because L-leucine must reach catabolic enzymes, transport studies are important for interpreting catabolic flux. L-type amino acid transporter 1-mediated transport at the inner blood-retinal barrier was characterized to understand leucine delivery to the retina. Localization studies using tagged proteins can reveal where catabolic enzymes reside and how they access L-leucine. These methods complement annotations to GO:0006552 by distinguishing transport from breakdown.
How CRISPR Can Be Used to Study GO:0006552 L-leucine catabolic process
Knockout
CRISPR knockout is used to delete candidate genes involved in L-leucine catabolism and then measure changes in leucine breakdown or downstream metabolites. For example, knocking out aminotransferases in Corynebacterium glutamicum can reveal their contribution to leucine flux and production. In host-pathogen studies, bacterial gene knockouts help determine whether specific metabolic genes are required for L-leucine-induced phenotypes. Knockout models provide causal evidence for gene function under GO:0006552.
Point Mutation
CRISPR point mutation introduces specific amino acid substitutions to test catalytic residues or regulatory sites in enzymes involved in L-leucine catabolism. This approach is valuable when a gene is essential and a complete knockout would be lethal. By altering redox-related or aminotransferase genes, researchers can dissect which residues control flux through leucine degradation. Point mutation models help refine the mechanistic understanding of GO:0006552.
Knock-in
CRISPR knock-in can add tags or reporter sequences to endogenous catabolic genes, enabling localization and interaction studies. Tagging transporters such as SLC7A5/LAT1 can reveal how L-leucine is delivered to catabolic compartments. Knock-in of fluorescent tags into metabolic genes also allows live-cell imaging of pathway components. These models support detailed cell biology of L-leucine catabolism.
Overexpression
CRISPR-mediated overexpression or cDNA overexpression can increase the abundance of a candidate catabolic enzyme to test whether it enhances L-leucine breakdown. In metabolic engineering, overexpressing key enzymes or altering redox flux has been used to improve L-leucine production, indirectly probing catabolic balance. Overexpression models are useful for gain-of-function studies of GO:0006552.
How EDITGENE Supports L-leucine catabolic process Research
Researchers studying L-leucine catabolic process-related genes often need to determine whether a candidate gene is causally involved in leucine breakdown, how specific mutations affect enzyme activity, and where the encoded protein acts within the cell. EDITGENE provides CRISPR-based cell models and screening services that enable these causal experiments, from knockout to precise point mutation and tagged knock-in, supported by bioinformatics for pathway annotation and hit prioritization.
Contact EDITGENE today to design your custom CRISPR model for L-leucine catabolic process research.
Frequently Asked Questions About L-leucine catabolic process
What is GO:0006552 L-leucine catabolic process?
GO:0006552 is a Gene Ontology biological process term defined as the chemical reactions and pathways resulting in the breakdown of L-leucine.
What genes are involved in L-leucine catabolic process?
Genes encoding aminotransferases, dehydrogenases, and related metabolic enzymes are involved, as shown in studies of Corynebacterium glutamicum and Escherichia coli.
Why is L-leucine catabolism important in biotechnology?
Modulating catabolic flux and redox balance improves L-leucine production in engineered strains such as C. glutamicum and E. coli.
How does L-leucine catabolism affect host-pathogen interactions?
L-leucine-induced metabolome changes can eliminate pathogens like Streptococcus iniae, linking leucine metabolism to infection outcomes.
Is L-leucine transport part of GO:0006552?
No, transport is a separate process; for example, SLC7A5/LAT1 mediates L-leucine transport at the inner blood-retinal barrier but is not itself catabolism.
What diseases are linked to L-leucine catabolism?
Branched-chain amino acid and L-leucine metabolism are studied in malnutrition, sarcopenia, and chronic liver disease.
Can CRISPR be used to study L-leucine catabolic process?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of genes involved in leucine breakdown.
What is the role of MiT/TFE family members in leucine-related cell death?
MiT/TFE family members suppress L-leucyl-L-leucine methyl ester-induced cell death, linking leucine derivatives to cell survival pathways.
How can I measure L-leucine catabolic flux?
Metabolomics and enzyme activity assays can quantify L-leucine consumption and product formation in cells or engineered strains.
What services does EDITGENE offer for GO:0006552 research?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services for studying L-leucine catabolic process.
Conclusion
GO:0006552 L-leucine catabolic process provides a precise ontology framework for studying how L-leucine is broken down across organisms. The verified literature shows that this process is central to metabolic engineering, host-pathogen interactions, cell death regulation, and clinical nutrition. By combining biochemical assays, metabolomics, and CRISPR-based genetic models, researchers can dissect the enzymes and regulatory nodes that control leucine catabolism. EDITGENE supports these efforts with customizable cell models and screening services tailored to GO:0006552.
References
- 1. Edagwa BJ et al.. 2009. Peptides containing gamma,delta-dihydroxy-L-leucine.. J Org Chem 74(11):4132-6 PMID: 19413277
- 2. Ding X et al.. 2023. High-level and -yield production of L-leucine in engineered Escherichia coli by multistep metabolic engineering.. Metab Eng 78:128-136 PMID: 37286072
- 3. Du CC et al.. 2017. Metabolic Mechanism for l-Leucine-Induced Metabolome To Eliminate Streptococcus iniae.. J Proteome Res 16(5):1880-1889 PMID: 28266220
- 4. Feng LY et al.. 2018. Improved l-Leucine Production in Corynebacterium glutamicum by Optimizing the Aminotransferases.. Molecules 23(9) PMID: 30134636
- 5. Yabuki A et al.. 2021. MiT/TFE family members suppress L-leucyl-L-leucine methyl ester-induced cell death.. J Toxicol Sci 46(3):143-156 PMID: 33642520
- 6. Tomi M et al.. 2005. L-type amino acid transporter 1-mediated L-leucine transport at the inner blood-retinal barrier.. Invest Ophthalmol Vis Sci 46(7):2522-30 PMID: 15980244
- 7. Wang YY et al.. 2019. Improvement of l-Leucine Production in Corynebacterium glutamicum by Altering the Redox Flux.. Int J Mol Sci 20(8) PMID: 31022947
- 8. Dos Santos ALS et al.. 2021. The impact of L-branched-chain amino acids and L-leucine on malnutrition, sarcopenia, and other outcomes in patients with chronic liver disease.. Expert Rev Gastroenterol Hepatol 15(2):181-194 PMID: 32993404
